Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AM00 | ISIN: SE0008241558 | Ticker-Symbol: 4A1
Frankfurt
06.06.25 | 08:01
0,965 Euro
-0,05 % -0,001
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CERENO SCIENTIFIC AB Chart 1 Jahr
5-Tage-Chart
CERENO SCIENTIFIC AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,9630,99517:14

Aktuelle News zur CERENO SCIENTIFIC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.05.Cereno Scientific - Firing on all cylinders247In Q125, Cereno made tangible progress across both its clinical programmes. The period opened with new data for lead asset CS1 indicating disease-modifying signals, and was capped by FDA endorsement...
► Artikel lesen
CERENO SCIENTIFIC Aktie jetzt für 0€ handeln
27.05.Cereno Scientific is nominated and shortlisted for 'Company of the Year' in the European Mediscience Awards 20251
23.05.Cereno Scientific AB: Cereno Scientific receives endorsement from FDA on plans for Phase IIb trial of CS1 in rare disease pulmonary arterial hypertension (PAH)97Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that...
► Artikel lesen
22.05.Cereno Scientific AB: Cereno Scientific publishes Interim Report for Q1 2025 (January 1 - March 31, 2025)138Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that...
► Artikel lesen
15.05.Cereno Scientific publishes Annual Report for 20241
13.05.Cereno Scientific presented CS1's Phase IIa trial results at the 5th Baltic Pulmonary Hypertension Conference 20252
09.05.Cereno Scientific give notice to attend the Annual General Meeting 20251
07.05.Correction: Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on June 10, 20251
07.05.Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on May 10, 20252
07.05.Cereno Scientific to present at ABGSC Investor Days on May 13-14, 2025, in Stockholm1
23.04.Cereno Scientific - CS1 takes another step towards Phase IIb267Cereno Scientific has successfully completed its planned Type C meeting with the FDA for lead asset CS1. The minutes from the meeting will be available after 30 days, but Cereno has indicated that the...
► Artikel lesen
22.04.Cereno Scientific aligns with FDA on CS1 development3
22.04.Cereno Scientific AB: Cereno Scientific completes successful FDA meeting discussing further clinical development of drug candidate CS1 in rare disease PAH160Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that...
► Artikel lesen
17.04.Cereno Scientific - CS014 completes Phase I, path clears for Phase II327Cereno Scientific has announced that its second clinical stage asset, CS014, has completed the Phase I safety study, with the conclusion of the second, multiple ascending dose (MAD) part of the trial...
► Artikel lesen
16.04.CERENO SCIENTIFIC: Cereno completes CS014 trial ahead of June top-line data1
16.04.Cereno Scientific AB: Cereno Scientific reports that its Phase I trial of CS014 has been concluded and confirms that top-line results are anticipated in June 2025119Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that...
► Artikel lesen
14.04.Cereno Scientific to attend BIO International Convention 2025 - largest and most comprehensive event for biotechnology1
17.03.Cereno Scientific AB: Cereno Scientific extends patent protection for drug candidate CS1 in the US and has filed to extend market exclusivity to 2045288Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that...
► Artikel lesen
12.03.Cereno Scientific secures FDA meeting to advance its development of CS1 for the treatment of rare disease PAH3
28.02.Cereno Scientific shares invitation to the webcast for the CS1 Phase IIa trial data presentation at 14:00 CET on March 41
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1